Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
NCT03912064Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2019
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab and CD25-depleted donor lymphocytes in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN) and 2 more, sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose for DLI at 6 weeks and Maximum Tolerated Dose for Ipilimumab at 6 weeks. Started Jul 2019; status: active, not recruiting.
02
Drugs
ipilimumabCD25-depleted donor lymphocytes
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)chronic myelomonocytic leukemia (CMML)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03912064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912064.